Vir Biotechnology stock: growth
VIRVir Biotechnology reported $68.56M in revenue for fiscal 2025, down 7.6% on the prior year, down 2.1% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2017 | |
|---|---|---|
| Revenue | −2.1% | 49.8% |
| Revenue per share | −5.0% | 3.1% |
| Earnings | no data | no data |
| Earnings per share | no data | no data |
| Free cash flow | no data | no data |
| Free cash flow per share | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2017 | $2.71M | −$69.85M | −$69.12M |
| 2018 | $10.67M | −$115.88M | −$102.29M |
| 2019 | $8.09M | −$174.68M | −$138.57M |
| 2020 | $76.37M | −$298.67M | −$197.49M |
| 2021 | $1.1B | $528.58M | −$69.41M |
| 2022 | $1.62B | $515.84M | $1.6B |
| 2023 | $86.18M | −$615.06M | −$800.36M |
| 2024 | $74.21M | −$521.96M | −$453.65M |
| 2025 | $68.56M | −$437.99M | −$396.61M |
Revenue by segment
How Vir Biotechnology, Inc. makes its money and how that has shifted. Names are as the company reports them.
- License And Collaboration Revenue$63.1M92%
- Grant$2.0M3%
- Other$3.4M5%
“Other” combines smaller and former segments with revenue the company does not assign to a segment. Names as reported, with abbreviations spelled out for the largest companies. The company split earlier years differently. A history would not be comparable, so only 2025 is shown.
Figures as a table
| 2025 | Share 2025 | |
|---|---|---|
| License And Collaboration Revenue | $63.13M | 92.1% |
| Grant | $2.04M | 3% |
| Other | $3.39M | 4.9% |
| Total revenue | $68.56M | 100% |
Revenue by region
Where Vir Biotechnology, Inc. generates its revenue.
- Outside the US94%
- United States3%
- Other3%
“Other” combines smaller regions with revenue the company does not assign to a region.
Figures as a table
| 2024 | 2025 | Share 2025 | |
|---|---|---|---|
| Outside the US | $60.31M | $64.27M | 93.7% |
| United States | $11.53M | $2.04M | 3% |
| Other | $2.37M | $2.25M | 3.3% |
| Total revenue | $74.21M | $68.56M | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 28 Oct 2026)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.